CorMedix Inc. 8K

CorMedix Therapeutics issued its Q2 2026 earnings release, reporting strong revenue and profitability growth, reaffirming revenue guidance while raising adjusted EBITDA guidance, and announcing a key DefenCath supply agreement and near-term REZZAYO sNDA submission plans.

On August 13, 2026, CorMedix Therapeutics reported its financial results for the quarter ended June 30, 2026, announcing consolidated revenue of $101.9 million, net income of $26.0 million, and adjusted EBITDA of $58.7 million, driven primarily by $66.1 million in DefenCath sales and $35.8 million from the acquired Melinta portfolio, while maintaining full-year 2026 revenue guidance of $325–$345 million and raising adjusted EBITDA guidance to $125–$140 million; the company also highlighted a new multi-year commercial supply agreement for DefenCath with a large dialysis operator that expands contracts to all top five U.S. dialysis providers, progress toward an sNDA submission with partner Mundipharma for REZZAYO prophylaxis in Q3 2026 with anticipated FDA action in H1 2027, and a strong liquidity position with $256.7 million in cash and short-term investments as of June 30, 2026.

Filing Facts

CIK

1410098

Ticker

CRMD

Form

8K

Source Type

fda

Accession

0001410098-26-000054

Alert Tier

6